Vectorite Biomedical Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 42.91 million compared to TWD 28.77 million a year ago. Net loss was TWD 26.41 million compared to net income of TWD 8.36 million a year ago.

Basic loss per share from continuing operations was TWD 0.6098 compared to basic earnings per share from continuing operations of TWD 0.1978 a year ago. Diluted loss per share from continuing operations was TWD 0.6098 compared to diluted earnings per share from continuing operations of TWD 0.1978 a year ago.